Stay Up to Date
Breaking News,
Updates, & More
Click Here to

TOP - May 2017, Vol 10, No 2

When added to treatment with docetaxel, the investigational drug plinabulin improved overall survival by 4.7 months in patients with advanced non–small-cell lung cancer with measurable lesions.
As options for second-line therapy for patients with metastatic renal-cell carcinoma continue to expand, so does the controversy surrounding optimal treatment selection.
As pharmacists’ responsibilities extend beyond dispensing medications to include advanced patient-centered services, many already meet the definition of nonphysician provider under Medicare Part B, yet they are often not reimbursed for their services.
In the May issue of The Oncology Pharmacist (TOP), we feature a conversation with Patrick J. Medina, PharmD, BCOP, Professor of Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy in Tulsa, in which he discusses changes to the reimbursement model, bridging the knowledge gap in a rapidly evolving field, and why provider status is the “holy grail” of pharmacy.
Although beneficence, autonomy, and justice comprise the bulwark of ethical principles in medicine, their prioritization has changed over the course of history.
Despite remarkable advancements in the treatment of cancer through the use of targeted agents and immunotherapy, outcomes are still varied, and, for some patients, these regimens provide only a short-term answer.
The advent of immunotherapy has led to durable clinical responses in a variety of malignancies, but identifying which patients will respond to treatment remains elusive.
Page 2 of 2
Results 11 - 17 of 17